FDA Approved a New Drug for the Treatment of Resistant Hypertension

Author: Dr. Ahmed Farhan     Published: 8 months ago 0 Replies

FDA Approved Aprocitentan, an endothelin receptor antagonist for the treatment of resistant hypertension [Ref].

Aprocitentan is to be marketed under the brand name, TRYVIO.

Aprocitentan is an endothelin receptor antagonist prescribed for the management of hypertension, in conjunction with other antihypertensive agents.

Its primary indication is to decrease blood pressure in adult patients inadequately responsive to other blood pressure-lowering medications.

By improving hypertension, TRYVIO effectively diminishes the risk of both fatal and non-fatal cardiovascular events, predominantly strokes and myocardial infarctions.

Aprocitentan Dose:

The recommended dose is 12.5 mg once daily

Who Should Not Be Prescribed Aprocitentan?

Aprocitentan is contraindicated in pregnant women.

It may also cause liver damage, anemia, fluid retention, allergic reactions, and male infertility.

It is not recommended in moderate to severe liver impairment and in advanced kidney disease (eGFR of <15 ml/minute)

Login to Reply

Money Back Guarantee
We return Money in 24 Hours

Secure online payment
We possess SSL / Secure Certificate

12/7 customer support
Well-trained & Supportive team

PMDC Verified Doctors
Authentic & updated information

emedz.net

Book Online and In-clinic appointments with your doctor. Consult via Video chat and get a prescription. Ask any question in the "Forum" section and get a detailed answer. Discuss your health issues. Advertisers who wish to place ads on emedz.net and reach multiple users can contact here: ads@emedz.net

Connect with us

Copyright @ 2024 - All Rights Reserved Reproduction of material from any pages without permission is strictly prohibited.